Skip to main content

Table 2 HIV (+) subject immunologic and HAART related characteristics

From: Increased pericardial fat accumulation is associated with increased intramyocardial lipid content and duration of highly active antiretroviral therapy exposure in patients infected with human immunodeficiency virus: a 3T cardiovascular magnetic resonance feasibility study

Immunologic characteristic Mean ± SD Range
Prevalence
HIV History
 Length of HIV diagnosis, months 196 ± 99 48–360
 Previous history of AIDS-defining diagnosis, % 25 ---
 Previous history of opportunistic infections, % 19 ---
 Undetectable viral load > 3 years, % 100 ---
 Compliance with HAART > 3 years, % 99 90–100
HAART-induced side effects
 Metabolic syndrome, % 22 ---
 Lipodystrophy, % 78 ---
 Lipoatrophy, % 63 ---
 Lipoaccumulation, % 67 ---
HAART Exposure
 Cumulative HAART (any agent), months 157 ± 88 36–336
 Cumulative exposure PI, months 91 ± 57 0–249
 Cumulative exposure NRTI, months 163 ± 122 40–464
 Cumulative exposure “high risk” PI, months 47 ± 33 0–103
 Cumulative exposure NNRTI, monthsa 22 ± 63 0–156
 Cumulative exposure INSTI, monthsa 5.5 ± 12.6 0–48
 Cumulative exposure “high risk” NRTI, monthsa 44.2 ± 73.9 0–273
Immunologic History
 CD4+ cell counta 594 ± 326 242–2597
 CD8+ cell counta 686 ± 356 312–1944
 CD4+/CD8+ ratioa 78 ± 47 30–313
  1. PI protease inhibitors, NRTI nucleoside reverse transcriptase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors, INSTI integrase strand transfer inhibitors, High risk PI’s amprenavir, fosampenavir, indinavir, lopinavir, High risk NRTI’s abacavir, didanosine
  2. aData reported as mean + standard deviation or median with interquartile range